All News

    What Patients With Breast Cancer Need to Know About Itovebi

    March 20th 2025, 7:05pm

    Article

    Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky.

    A Heaven-Sent Sign About My Brother’s Lymphoma

    March 20th 2025, 5:00pm

    Article

    Cancer runs in the family, and after I’d dealt with two breast cancers, my brother came down with lymphoma.

    Golidocitinib Plus PD-1 Antibodies Being Explored in Lung Cancer Subset

    March 20th 2025, 4:08pm

    Article

    Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will be presented this month.

    Development of EO-3021 Discontinued for Gastric and GEJ Cancers

    March 20th 2025, 3:02pm

    Article

    Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows insufficient efficacy.

    Kadcyla Continues to Show Benefits in Early HER2+ Breast Cancer

    March 20th 2025, 1:00pm

    Video

    In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.

    Gene Expression Testing and Targeted Therapies in Breast Cancer Care

    March 19th 2025, 9:00pm

    Article

    Gene expression testing helps determine chemotherapy needs for HR+ breast cancer, optimizing treatment and reducing unnecessary toxicity.

    FDA Approves Keytruda in HER2+ Gastric, Gastroesophageal Junction Cancer

    March 19th 2025, 6:29pm

    Article

    The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

    Painting an Accurate Portrait of Breast Cancer Survivorship

    March 19th 2025, 5:00pm

    Article

    As a breast cancer survivor, I feel it is incumbent upon me to give an accurate picture of cancer to others, particularly newly diagnosed patients.

    Fruzaqla Plus Sintilimab May Slow Renal Cell Carcinoma Progression

    March 19th 2025, 4:00pm

    Article

    Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

    FDA Grants Compassionate Use Treatment to Namodenoson in Pancreatic Cancer

    March 19th 2025, 3:00pm

    Article

    The FDA has granted approval to an act of compassionate use treatment with the anti-cancer drug Namodenoson for a patient with pancreatic cancer.